Hogan Lovells advises HAEMATO AG on the sale of HAEMATO Pharm GmbH to PHOENIX group

Press releases | 20 October 2025

Led by partner Dr. Jan Philipp Feigen, global law firm Hogan Lovells has advised HAEMATO AG, a majority-owned subsidiary of M1 Kliniken AG, on the sale of all shares in its subsidiary HAEMATO Pharm GmbH to PHOENIX group, one of Europe’s leading healthcare providers headquartered in Mannheim.

Completion of the transaction is subject to customary antitrust approvals. The parties have agreed not to disclose the financial terms of the transaction.

HAEMATO Pharm GmbH is a parallel importer specializing in therapies in the areas of HIV/AIDS, neurology, oncology, rheumatology, and ophthalmology.

With this transaction, M1 Kliniken AG continues to pursue its strategic path of positioning itself as the world’s leading vertically integrated pure-play provider in the field of medical aesthetics.

Hogan Lovells team for HAEMATO AG:

Dr. Jan Philipp Feigen (Partner), Dr. Malte Ingwersen (Counsel), Dr. Sebastian Merkel (Associate), Björn Thorben Stute (Projects Associate) (all Private Equity, Hamburg);

Christian Ritz (Partner), Dr. Dennis Cukurov (Senior Associate) (both Antitrust, Munich);

Dr. Falk Loose (Counsel), Peter Volkmann (Senior Associate) (both Tax, Munich).